249 related articles for article (PubMed ID: 26884284)
1. Assessment of OPG, RANKL, bone turnover markers serum levels and BMD after treatment with strontium ranelate and ibandronate in patients with postmenopausal osteoporosis.
Stuss M; Sewerynek E; Król I; Stępień-Kłos W; Jędrzejczyk S
Endokrynol Pol; 2016; 67(2):174-84. PubMed ID: 26884284
[TBL] [Abstract][Full Text] [Related]
2. Assessment of OPG/RANK/RANKL gene expression levels in peripheral blood mononuclear cells (PBMC) after treatment with strontium ranelate and ibandronate in patients with postmenopausal osteoporosis.
Stuss M; Rieske P; Cegłowska A; Stêpień-Kłos W; Liberski PP; Brzeziańska E; Sewerynek E
J Clin Endocrinol Metab; 2013 May; 98(5):E1007-11. PubMed ID: 23543663
[TBL] [Abstract][Full Text] [Related]
3. Effects of alendronate treatment on serum levels of osteoprotegerin and total receptor activator of nuclear factor kappaB in women with postmenopausal osteoporosis.
Reyes-García R; Muñoz-Torres M; García DF; Mezquita-Raya P; García Salcedo JA; de Dios Luna J
Menopause; 2010; 17(1):140-4. PubMed ID: 19574937
[TBL] [Abstract][Full Text] [Related]
4. Serum osteoprotegerin and RANKL are not specifically altered in women with postmenopausal osteoporosis treated with teriparatide or risedronate: a randomized, controlled trial.
Anastasilakis AD; Goulis DG; Polyzos SA; Gerou S; Koukoulis G; Kita M; Avramidis A
Horm Metab Res; 2008 Apr; 40(4):281-5. PubMed ID: 18275008
[TBL] [Abstract][Full Text] [Related]
5. Effects of raloxifene therapy on circulating osteoprotegerin and RANK ligand levels in post-menopausal osteoporosis.
Fernández-García D; Muñoz-Torres M; Mezquita-Raya P; de la Higuera M; Alonso G; Reyes-García R; Ochoa AS; Ruiz-Requena ME; Luna JD; Escobar-Jiménez F
J Endocrinol Invest; 2008 May; 31(5):416-21. PubMed ID: 18560259
[TBL] [Abstract][Full Text] [Related]
6. Acute changes in serum osteoprotegerin and receptor activator for nuclear factor-kappaB ligand levels in women with established osteoporosis treated with teriparatide.
Anastasilakis AD; Goulis DG; Polyzos SA; Gerou S; Pavlidou V; Koukoulis G; Avramidis A
Eur J Endocrinol; 2008 Mar; 158(3):411-5. PubMed ID: 18299476
[TBL] [Abstract][Full Text] [Related]
7. Strontium fructose 1,6-diphosphate prevents bone loss in a rat model of postmenopausal osteoporosis via the OPG/RANKL/RANK pathway.
Ma B; Zhang Q; Wu D; Wang YL; Hu YY; Cheng YP; Yang ZD; Zheng YY; Ying HJ
Acta Pharmacol Sin; 2012 Apr; 33(4):479-89. PubMed ID: 22426695
[TBL] [Abstract][Full Text] [Related]
8. Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients.
Dobnig H; Hofbauer LC; Viereck V; Obermayer-Pietsch B; Fahrleitner-Pammer A
Osteoporos Int; 2006; 17(5):693-703. PubMed ID: 16435076
[TBL] [Abstract][Full Text] [Related]
9. Relationships among serum receptor of nuclear factor-kappaB ligand, osteoprotegerin, high-sensitivity C-reactive protein, and bone mineral density in postmenopausal women: osteoimmunity versus osteoinflammatory.
Nabipour I; Larijani B; Vahdat K; Assadi M; Jafari SM; Ahmadi E; Movahed A; Moradhaseli F; Sanjdideh Z; Obeidi N; Amiri Z
Menopause; 2009; 16(5):950-5. PubMed ID: 19387415
[TBL] [Abstract][Full Text] [Related]
10. Receptor activator of NF(Kappa)B ligand/osteoprotegerin (RANKL/OPG) system and osteopontin (OPN) serum levels in a population of apulian postmenopausal women.
D'Amore M; Fanelli M; D'Amore S; Fontana A; Minenna G
Panminerva Med; 2006 Dec; 48(4):215-21. PubMed ID: 17215793
[TBL] [Abstract][Full Text] [Related]
11. Regulatory effect of parathyroid hormone on sRANKL-osteoprotegerin in hemodialysis patients with renal bone disease.
Doumouchtsis K; Perrea D; Doumouchtsis S; Tziamalis M; Poulakou M; Vlachos I; Kostakis A
Ther Apher Dial; 2009 Feb; 13(1):49-55. PubMed ID: 19379170
[TBL] [Abstract][Full Text] [Related]
12. Multiparameter analysis of serum levels of C-telopeptide crosslaps, bone-specific alkaline phosphatase, cathepsin K, osteoprotegerin and receptor activator of nuclear factor κB ligand in the diagnosis of osteoporosis.
Piatek S; Adolf D; Wex T; Halangk W; Klose S; Westphal S; Amthauer H; Winckler S
Maturitas; 2013 Apr; 74(4):363-8. PubMed ID: 23391500
[TBL] [Abstract][Full Text] [Related]
13. Higher levels of s-RANKL and osteoprotegerin in children and adolescents with type 1 diabetes mellitus may indicate increased osteoclast signaling and predisposition to lower bone mass: a multivariate cross-sectional analysis.
Tsentidis C; Gourgiotis D; Kossiva L; Doulgeraki A; Marmarinos A; Galli-Tsinopoulou A; Karavanaki K
Osteoporos Int; 2016 Apr; 27(4):1631-1643. PubMed ID: 26588909
[TBL] [Abstract][Full Text] [Related]
14. Serum OPG and RANKL levels before and after intravenous bisphosphonate treatment in Paget's disease of bone.
Martini G; Gennari L; Merlotti D; Salvadori S; Franci MB; Campagna S; Avanzati A; De Paola V; Valleggi F; Nuti R
Bone; 2007 Feb; 40(2):457-63. PubMed ID: 16979395
[TBL] [Abstract][Full Text] [Related]
15. Association between osteoprotegerin (OPG), receptor activator of nuclear factor-kappaB (RANK), and RANK ligand (RANKL) gene polymorphisms and circulating OPG, soluble RANKL levels, and bone mineral density in Korean postmenopausal women.
Kim JG; Kim JH; Kim JY; Ku SY; Jee BC; Suh CS; Kim SH; Choi YM
Menopause; 2007; 14(5):913-8. PubMed ID: 17667143
[TBL] [Abstract][Full Text] [Related]
16. Changes in the serum levels of osteoprotegerin and soluble receptor activator for nuclear factor kappaB ligand after estrogen-progestogen therapy and their relationships with changes in bone mass in postmenopausal women.
Kim JG; Kim JH; Lee DO; Kim H; Kim JY; Suh CS; Kim SH; Choi YM
Menopause; 2008; 15(2):357-62. PubMed ID: 17925661
[TBL] [Abstract][Full Text] [Related]
17. The effect of risedronate treatment on serum cytokines in postmenopausal osteoporosis: a 6-month randomized and controlled study.
Dundar U; Kavuncu V; Ciftci IH; Evcik D; Solak O; Cakir T
J Bone Miner Metab; 2009; 27(4):464-70. PubMed ID: 19301089
[TBL] [Abstract][Full Text] [Related]
18. No difference between strontium ranelate (SR) and calcium/vitamin D on bone turnover markers in women with established osteoporosis previously treated with teriparatide: a randomized controlled trial.
Anastasilakis AD; Goulis DG; Polyzos SA; Gerou S; Ballaouri I; Efstathiadou Z; Kita M; Avramidis A
Clin Endocrinol (Oxf); 2009 Apr; 70(4):522-6. PubMed ID: 18625000
[TBL] [Abstract][Full Text] [Related]
19. The effect of prior bisphosphonate therapy on the subsequent BMD and bone turnover response to strontium ranelate.
Middleton ET; Steel SA; Aye M; Doherty SM
J Bone Miner Res; 2010 Mar; 25(3):455-62. PubMed ID: 20201000
[TBL] [Abstract][Full Text] [Related]
20. Effect of recent spinal cord injury on the OPG/RANKL system and its relationship with bone loss and the response to denosumab therapy.
Gifre L; Ruiz-Gaspà S; Carrasco JL; Portell E; Vidal J; Muxi A; Monegal A; Guañabens N; Peris P
Osteoporos Int; 2017 Sep; 28(9):2707-2715. PubMed ID: 28580511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]